Factor VIII products: key aspects of development, clinical research and use (part 1)
According to the World Federation of Hemophilia (WFH), there are currently about 400 thousand patients with hemophilia in the world. Severe clinical manifestations of the disease associated with a genetically determined deficiency of blood clotting factor activity require continuous replacement ther...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2021-03-01
|
| Series: | Биопрепараты: Профилактика, диагностика, лечение |
| Subjects: | |
| Online Access: | https://www.biopreparations.ru/jour/article/view/313 |
| _version_ | 1797244465416503296 |
|---|---|
| author | Zh. I. Avdeeva A. A. Soldatov V. P. Bondarev V. D. Mosyagin V. A. Merkulov |
| author_facet | Zh. I. Avdeeva A. A. Soldatov V. P. Bondarev V. D. Mosyagin V. A. Merkulov |
| author_sort | Zh. I. Avdeeva |
| collection | DOAJ |
| description | According to the World Federation of Hemophilia (WFH), there are currently about 400 thousand patients with hemophilia in the world. Severe clinical manifestations of the disease associated with a genetically determined deficiency of blood clotting factor activity require continuous replacement therapy with blood clotting medicines. Long-term use of protein-based medicines often leads to the formation of specific antibodies, which causes a decrease in or loss of efficacy of the medicine or results in severe adverse reactions, including anaphylaxis. Therefore, it is important to search for new optimal approaches to hemophilia treatment, which requires the development of new blood clotting factor products, improvement of the production technology for already authorised products, as well as the use of non-factor products. The aim of the study was to present the results of the analysis of key issues related to the development and characteristics of plasma-derived and recombinant factor VIII products, new approaches to hemophilia A treatment, including the use of non-factor products. The review summarises current data on the etiology, clinical manifestations, and complications of hemophilia A treatment. It provides information on the blood clotting factor products (plasma-derived and recombinant) used as replacement therapy. It also provides information on advanced research projects for the development of new biotechnology-derived products which have good prospects of successful clinical use. |
| first_indexed | 2024-03-08T21:43:47Z |
| format | Article |
| id | doaj.art-1f8ca495c0374294b6614e09689b210a |
| institution | Directory Open Access Journal |
| issn | 2221-996X 2619-1156 |
| language | Russian |
| last_indexed | 2024-04-24T19:11:26Z |
| publishDate | 2021-03-01 |
| publisher | Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Биопрепараты: Профилактика, диагностика, лечение |
| spelling | doaj.art-1f8ca495c0374294b6614e09689b210a2024-03-26T09:10:53ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562021-03-01211394910.30895/2221-996X-2021-21-1-39-49235Factor VIII products: key aspects of development, clinical research and use (part 1)Zh. I. Avdeeva0A. A. Soldatov1V. P. Bondarev2V. D. Mosyagin3V. A. Merkulov4Scientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal Products; I. M. Sechenov First Moscow State Medical UniversityAccording to the World Federation of Hemophilia (WFH), there are currently about 400 thousand patients with hemophilia in the world. Severe clinical manifestations of the disease associated with a genetically determined deficiency of blood clotting factor activity require continuous replacement therapy with blood clotting medicines. Long-term use of protein-based medicines often leads to the formation of specific antibodies, which causes a decrease in or loss of efficacy of the medicine or results in severe adverse reactions, including anaphylaxis. Therefore, it is important to search for new optimal approaches to hemophilia treatment, which requires the development of new blood clotting factor products, improvement of the production technology for already authorised products, as well as the use of non-factor products. The aim of the study was to present the results of the analysis of key issues related to the development and characteristics of plasma-derived and recombinant factor VIII products, new approaches to hemophilia A treatment, including the use of non-factor products. The review summarises current data on the etiology, clinical manifestations, and complications of hemophilia A treatment. It provides information on the blood clotting factor products (plasma-derived and recombinant) used as replacement therapy. It also provides information on advanced research projects for the development of new biotechnology-derived products which have good prospects of successful clinical use.https://www.biopreparations.ru/jour/article/view/313hemophilia acoagulation factor viiifactor viii products (blood plasma products, recombinant products)new approaches to hemophilia treatment |
| spellingShingle | Zh. I. Avdeeva A. A. Soldatov V. P. Bondarev V. D. Mosyagin V. A. Merkulov Factor VIII products: key aspects of development, clinical research and use (part 1) Биопрепараты: Профилактика, диагностика, лечение hemophilia a coagulation factor viii factor viii products (blood plasma products, recombinant products) new approaches to hemophilia treatment |
| title | Factor VIII products: key aspects of development, clinical research and use (part 1) |
| title_full | Factor VIII products: key aspects of development, clinical research and use (part 1) |
| title_fullStr | Factor VIII products: key aspects of development, clinical research and use (part 1) |
| title_full_unstemmed | Factor VIII products: key aspects of development, clinical research and use (part 1) |
| title_short | Factor VIII products: key aspects of development, clinical research and use (part 1) |
| title_sort | factor viii products key aspects of development clinical research and use part 1 |
| topic | hemophilia a coagulation factor viii factor viii products (blood plasma products, recombinant products) new approaches to hemophilia treatment |
| url | https://www.biopreparations.ru/jour/article/view/313 |
| work_keys_str_mv | AT zhiavdeeva factorviiiproductskeyaspectsofdevelopmentclinicalresearchandusepart1 AT aasoldatov factorviiiproductskeyaspectsofdevelopmentclinicalresearchandusepart1 AT vpbondarev factorviiiproductskeyaspectsofdevelopmentclinicalresearchandusepart1 AT vdmosyagin factorviiiproductskeyaspectsofdevelopmentclinicalresearchandusepart1 AT vamerkulov factorviiiproductskeyaspectsofdevelopmentclinicalresearchandusepart1 |